Typical carcinoid arising in mature teratoma of anterior mediastinum

Department of Pathology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
Asian cardiovascular & thoracic annals 02/2012; 20(1):80-2. DOI: 10.1177/0218492311428185
Source: PubMed


Teratoma is the second most common mediastinal neoplasm, but malignant transformation in mature teratomas is uncommon at both gonadal and extragonadal sites. A 35-year-old woman presented with an anterior mediastinal mass. Computed tomography suggested a teratoma. Meticulous pathological examination helped in detecting a neuroendocrine neoplasm (carcinoid) within the mature teratoma. Malignant transformation in a teratoma is difficult to diagnose on clinical and radiological assessment; histopathology is essential to detect the malignant nature of these neoplasms.

Download full-text


Available from: Niraj Kumari, Sep 24, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background. A carcinoid arising from a mature cystic teratoma of the mediastinum is rare. Case. A 38-year-old man was admitted to our hospital for evaluation of an abnormal shadow on a chest radiograph. Chest CT scan and MRI showed a well-defined mass with calcification and heterogeneous components in the right anterior mediastinum. Video-assisted thoracic surgery was performed to resect the tumor, which was suspected to be a mediastinal teratoma. The histopathological diagnosis was a carcinoid arising from a mature cystic teratoma of the mediastinum. Conclusion. We report a rare case of a carcinoid arising from a mature cystic teratoma of the mediastinum.
    Haigan 12/2012; 52(7):1047-1051. DOI:10.2482/haigan.52.1047
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A 36-year-old woman had presented with dry cough for 2 months. Thoracic computed tomography (CT) scan showed a 12 cm × 8 cm ×5 cm mass in the anterior mediastinum. Due to intimately involving the aortic arch, tumor was removed incompletely. Residual tumor remained approximate 2 cm × 3 cm × 4 cm. Histologic diagnosis was a mature cystic teratoma containing a carcinoid. Subsequently, radiotherapy (RT) was administrated on residual tumor for a total dose of 50 Gy at 2 Gy/d fraction in 25 fractions. At 2-year follow-up, the patient had stable disease. In conclusion, adjuvant radiotherapy with 50 Gy is an effective approach for residual tumor of mediastinal carcinoid teratoma.
    Journal of Thoracic Disease 04/2013; 5(2):E61-4. DOI:10.3978/j.issn.2072-1439.2012.11.11 · 1.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: HER2 is an important determinant of poor prognosis in breast cancer patients. Studies indicate that HER2 positive tumors are mostly resistant to therapy and have high metastatic potential however, the underlying mechanisms remain unknown. In this study, MDA-MB-231 and MCF-7 breast cancer cells with their HER2 overexpressing syngeneic variants were used to delineate the role of HER2 in EMT and metastasis. Our results demonstrated that HER2 overexpression increased the invasive potential of cells. Our results also showed that HER2 overexpression lead to the production of TGFβ resulting in the activation of TGFβ/SMAD signaling. Furthermore, activation of SNAIL, SLUG and ZEB-1, the transcriptional repressors of E-cadherin and increased mesenchymal characteristics were observed in high HER2 cells. Interestingly, EMT by HER2 was mediated through TGFβ. Intravenous injection of high HER2 MDA-MB-231 (HH) cells in athymic nude mice showed early and substantial metastasis as compared to the parent cells establishing the direct role of HER2 in metastasis. Our results showed that inhibition of HER2 mediated EMT by cucurbitacin B a triterpenoid, resulted in the suppression of brain metastasis of breast cancer cells. Taken together, our results identify a novel mechanism of HER2 in promoting breast cancer metastasis through de novo synthesis of TGFβ leading to EMT, an initial and essential step of metastasis.
    Molecular Oncology 06/2014; 8(8). DOI:10.1016/j.molonc.2014.06.006 · 5.33 Impact Factor
Show more